Sales of Opdivo, Keytruda and related drugs for lung cancer will exceed $20 billion in 2022, according to Cowen. Bristol’s Opdivo and Merck’s Keytruda are shaping up to be two of the biggest blockbusters for the pharmaceutical industry. PhotoTaking on lung cancer use has provided the most glittering prize. That is when a trial of Opdivo in combination with another drug for treating lung cancer should report. Bristol-Myers Squibb has suffered a $21 billion self-inflicted wound.

Source: New York Times August 05, 2016 18:03 UTC